Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17581179 | 0.90 | CHRM2 (0.43) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL23027707 | 0.90 | POLB (0.41) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17581281 | 0.82 | NOS3 (0.42) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17581284 | 0.82 | NOS3 (0.42) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17581176 | 0.76 | CHRM2 (0.43) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20281459 | 0.74 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20145042 | 0.73 | PDE3B (0.47) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20144818 | 0.72 | IL1B (0.50) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20145073 | 0.72 | IL1B (0.50) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20145024 | 0.72 | TDO2 (0.48) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | CHRM2 4331/4885CHRM1 4830/4885CHRM3 4327/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CHRM2 4331/4885CHRM1 4830/4885CHRM3 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.